MOHN KG, Zhou F, Brokstad KA, Sridhar S, et al. Live attenuated influenza vaccination boosts durable cross-reactive and protection-associated T-cells in children. J Infect Dis. 2017 Mar 27. doi: 10.1093
Background:
Live attenuated influenza vaccines (LAIV) stimulate a multifaceted immune response including cellular immunity, which may provide protection against newly emerging strains. This study shows proof of concept that LAIV boosts pre-existing, cross-reactive T-cells in children to genetically diverse influenza A strains to which the children had not been exposed.
Methods:
We studied the long-term cross-reactive T-cell response in 14 trivalent LAIV vaccinated children using the fluorescent immunospot assay (FluroSpot) with heterologous H1N1 and H3N2 influenza A viruses and CD8 peptides from the internal proteins (M1, NP, PB1). Serum antibody responses were determined by the Hemagglutination Inhibition (HI). Blood samples were collected before vaccination and up to one year post-vaccination.
Results:
Pre-existing cross-reactive T-cells to genetically diverse influenza A strains were found in the majority of the children, which were further boosted in 50% of the children after LAIV. Further analyses of these T-cells showed significant increases in CD8+ T-cells, mainly dominated by NP specific responses. After LAIV, the youngest children showed the highest increase in T-cell responses.
Conclusion:
LAIV boosts durable, cross-reactive T-cell responses in children and may have a clinically protective effect at the population level. LAIV may be a first step towards the desired universal influenza vaccine.
Live attenuated influenza vaccines (LAIV) stimulate a multifaceted immune response including cellular immunity, which may provide protection against newly emerging strains. This study shows proof of concept that LAIV boosts pre-existing, cross-reactive T-cells in children to genetically diverse influenza A strains to which the children had not been exposed.
Methods:
We studied the long-term cross-reactive T-cell response in 14 trivalent LAIV vaccinated children using the fluorescent immunospot assay (FluroSpot) with heterologous H1N1 and H3N2 influenza A viruses and CD8 peptides from the internal proteins (M1, NP, PB1). Serum antibody responses were determined by the Hemagglutination Inhibition (HI). Blood samples were collected before vaccination and up to one year post-vaccination.
Results:
Pre-existing cross-reactive T-cells to genetically diverse influenza A strains were found in the majority of the children, which were further boosted in 50% of the children after LAIV. Further analyses of these T-cells showed significant increases in CD8+ T-cells, mainly dominated by NP specific responses. After LAIV, the youngest children showed the highest increase in T-cell responses.
Conclusion:
LAIV boosts durable, cross-reactive T-cell responses in children and may have a clinically protective effect at the population level. LAIV may be a first step towards the desired universal influenza vaccine.
See Also:
Latest articles in those days:
- The evolution and transmission dynamics of H3N2 influenza virus identified in a respiratory disease outbreak in companion dogs in Alabama, USA 11 hours ago
- Structural and functional characterization of hemagglutinin E190D and Q226H minor variants in human H5N1 A/British Columbia/PHL-2032/2024 11 hours ago
- Spatial risk factors associated with outbreaks of highly pathogenic avian influenza in Pennsylvania’s commercial poultry farms 11 hours ago
- [preprint]H9N2 avian influenza virus in Bangladesh: three genetically distinct co-circulating subgroups retain a largely conserved antigenic phenotype 11 hours ago
- [preprint]Endogenous serine proteases in MDCK sublines support trypsin-independent influenza A virus replication 11 hours ago
[Go Top] [Close Window]


